导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -20.87% | 4436/4773 |
| 近一周 | -2.20% | 3562/5465 |
| 近一月 | -6.19% | 4077/5421 |
| 近一季 | -1.20% | 1186/5231 |
| 近半年 | -14.56% | 3998/4920 |
| 近一年 | -30.96% | 4241/4394 |
| 近两年 | 20.00% | 2650/2954 |
| 近三年 | 4.79% | 1847/2253 |
| 成立以来 | -0.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.10% 4621/4961 |
-10.70% 4158/5312 |
- - |
- - |
| 2025 | 22.26% 1985/4813 |
22.08% 57/3635 |
-0.96% 3078/4076 |
21.37% 1808/4524 |
-16.68% 4390/4813 |
| 2024 | 18.60% 589/3463 |
-7.91% 2206/2808 |
2.64% 326/3014 |
26.69% 252/3129 |
-0.97% 1555/3463 |
| 2023 | -13.00% 1516/2656 |
-2.04% 1918/2280 |
-3.48% 803/2385 |
-4.84% 1238/2515 |
-3.31% 652/2655 |
| 2022 | -24.78% 1256/2207 |
-23.31% 1728/1919 |
12.62% 240/2016 |
-24.28% 1985/2113 |
15.02% 75/2208 |
| 2021 | -21.05% 1177/1822 |
-4.50% 869/1255 |
7.87% 662/1330 |
-14.43% 1369/1466 |
-10.44% 1603/1822 |
| 2020 | 40.75% 304/1250 |
-9.82% 722/1028 |
25.11% 161/1067 |
7.19% 798/1164 |
16.39% 175/1184 |
| 2019 | - - |
- - |
-3.39% 388/788 |
0.59% 505/850 |
8.12% 350/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实港股通新经济指数C VS. 长安沪深300非周期A(740101) |